Analysts Set Expectations for Alumis FY2029 Earnings

Alumis Inc. (NASDAQ:ALMS) – Research analysts at Leerink Partnrs issued their FY2029 EPS estimates for Alumis in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings of ($1.61) per share for the year. The consensus estimate for Alumis’ current full-year earnings is ($8.45) per share.

Several other research analysts have also recently issued reports on ALMS. Robert W. Baird assumed coverage on shares of Alumis in a report on Thursday, October 31st. They issued an “outperform” rating and a $25.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a research report on Thursday, November 14th. Oppenheimer started coverage on Alumis in a report on Thursday, January 30th. They issued an “outperform” rating and a $32.00 price objective for the company. Baird R W raised Alumis to a “strong-buy” rating in a report on Thursday, October 31st. Finally, HC Wainwright cut their price target on shares of Alumis from $26.00 to $19.00 and set a “buy” rating for the company in a report on Friday. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Alumis has a consensus rating of “Buy” and an average price target of $26.57.

Alumis Price Performance

Alumis stock opened at $5.67 on Thursday. Alumis has a 52 week low of $4.86 and a 52 week high of $13.53. The company’s 50-day moving average price is $7.87 and its two-hundred day moving average price is $10.27.

Hedge Funds Weigh In On Alumis

A number of institutional investors have recently bought and sold shares of ALMS. BNP Paribas Financial Markets purchased a new position in shares of Alumis in the third quarter worth approximately $27,000. MetLife Investment Management LLC acquired a new position in Alumis in the 3rd quarter worth approximately $89,000. China Universal Asset Management Co. Ltd. purchased a new position in Alumis during the 4th quarter worth approximately $79,000. JPMorgan Chase & Co. acquired a new stake in Alumis during the 3rd quarter valued at $191,000. Finally, Barclays PLC purchased a new stake in shares of Alumis in the third quarter valued at $197,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.